167 related articles for article (PubMed ID: 31355539)
1. Mek Inhibitor Reverses Hypertrophic Cardiomyopathy in RIT1 Mutated Noonan Syndrome: For the first time, hypertrophic cardiomyopathy was reversed in Noonan syndrome associated with a RIT1 mutation.
Am J Med Genet A; 2019 Aug; 179(8):1408-1409. PubMed ID: 31355539
[No Abstract] [Full Text] [Related]
2. Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition.
Andelfinger G; Marquis C; Raboisson MJ; Théoret Y; Waldmüller S; Wiegand G; Gelb BD; Zenker M; Delrue MA; Hofbeck M
J Am Coll Cardiol; 2019 May; 73(17):2237-2239. PubMed ID: 31047013
[No Abstract] [Full Text] [Related]
3. MEK Inhibition for RASopathy-Associated Hypertrophic Cardiomyopathy: Clinical Application of a Basic Concept.
Chaput D; Andelfinger G
Can J Cardiol; 2024 May; 40(5):789-799. PubMed ID: 38432396
[TBL] [Abstract][Full Text] [Related]
4. Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan Syndrome.
Leegaard A; Gregersen PA; Nielsen TØ; Bjerre JV; Handrup MM
Eur J Med Genet; 2022 Nov; 65(11):104630. PubMed ID: 36184070
[TBL] [Abstract][Full Text] [Related]
5. Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation.
Lioncino M; Fusco A; Monda E; Colonna D; Sibilio M; Caiazza M; Magri D; Borrelli AC; D'Onofrio B; Mazzella ML; Colantuono R; Arienzo MR; Sarubbi B; Russo MG; Chello G; Limongelli G
Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140671
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.
Takahashi K; Kogaki S; Kurotobi S; Nasuno S; Ohta M; Okabe H; Wada K; Sakai N; Taniike M; Ozono K
Eur J Pediatr; 2005 Aug; 164(8):497-500. PubMed ID: 15889278
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
Aoki Y; Niihori T; Banjo T; Okamoto N; Mizuno S; Kurosawa K; Ogata T; Takada F; Yano M; Ando T; Hoshika T; Barnett C; Ohashi H; Kawame H; Hasegawa T; Okutani T; Nagashima T; Hasegawa S; Funayama R; Nagashima T; Nakayama K; Inoue S; Watanabe Y; Ogura T; Matsubara Y
Am J Hum Genet; 2013 Jul; 93(1):173-80. PubMed ID: 23791108
[TBL] [Abstract][Full Text] [Related]
8. Molecular Management of Multifocal Atrial Tachycardia in Noonan's Syndrome With MEK1/2 Inhibitor Trametinib.
Meisner JK; Bradley DJ; Russell MW
Circ Genom Precis Med; 2021 Oct; 14(5):e003327. PubMed ID: 34463117
[No Abstract] [Full Text] [Related]
9. [RIT1: a novel gene associated with Noonan syndrome].
Arroyo-Carrera I; Solo de Zaldivar-Tristancho M; Martin-Fernandez R; Vera-Torres M; Gonzalez de Buitrago-Amigo JF; Botet-Rodriguez J
Rev Neurol; 2016 Oct; 63(8):358-362. PubMed ID: 27699752
[TBL] [Abstract][Full Text] [Related]
10. Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.
Levin MD; Saitta SC; Gripp KW; Wenger TL; Ganesh J; Kalish JM; Epstein MR; Smith R; Czosek RJ; Ware SM; Goldenberg P; Myers A; Chatfield KC; Gillespie MJ; Zackai EH; Lin AE
Am J Med Genet A; 2018 Aug; 176(8):1711-1722. PubMed ID: 30055033
[TBL] [Abstract][Full Text] [Related]
11. [Gene mutation and clinical phenotype analysis of patients with Noonan syndrome and hypertrophic cardiomyopathy].
Liu XH; Ding WW; Han L; Liu XR; Xiao YY; Yang J; Mo Y
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):780-784. PubMed ID: 29050118
[No Abstract] [Full Text] [Related]
12. New Noonan syndrome model mice with RIT1 mutation exhibit cardiac hypertrophy and susceptibility to β-adrenergic stimulation-induced cardiac fibrosis.
Takahara S; Inoue SI; Miyagawa-Tomita S; Matsuura K; Nakashima Y; Niihori T; Matsubara Y; Saiki Y; Aoki Y
EBioMedicine; 2019 Apr; 42():43-53. PubMed ID: 30898653
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.
Yaoita M; Niihori T; Mizuno S; Okamoto N; Hayashi S; Watanabe A; Yokozawa M; Suzumura H; Nakahara A; Nakano Y; Hokosaki T; Ohmori A; Sawada H; Migita O; Mima A; Lapunzina P; Santos-Simarro F; García-Miñaúr S; Ogata T; Kawame H; Kurosawa K; Ohashi H; Inoue S; Matsubara Y; Kure S; Aoki Y
Hum Genet; 2016 Feb; 135(2):209-22. PubMed ID: 26714497
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular disease in Noonan syndrome.
Pierpont ME; Digilio MC
Curr Opin Pediatr; 2018 Oct; 30(5):601-608. PubMed ID: 30024444
[TBL] [Abstract][Full Text] [Related]
15. Genotype and phenotype in patients with Noonan syndrome and a RIT1 mutation.
Kouz K; Lissewski C; Spranger S; Mitter D; Riess A; Lopez-Gonzalez V; Lüttgen S; Aydin H; von Deimling F; Evers C; Hahn A; Hempel M; Issa U; Kahlert AK; Lieb A; Villavicencio-Lorini P; Ballesta-Martinez MJ; Nampoothiri S; Ovens-Raeder A; Puchmajerová A; Satanovskij R; Seidel H; Unkelbach S; Zabel B; Kutsche K; Zenker M
Genet Med; 2016 Dec; 18(12):1226-1234. PubMed ID: 27101134
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibition in BRAF-mutated melanoma.
MacKenzie A; Boycott K
N Engl J Med; 2012 Oct; 367(14):1364-5. PubMed ID: 23034029
[No Abstract] [Full Text] [Related]
17. MEK inhibition in BRAF-mutated melanoma.
Ascierto PA
N Engl J Med; 2012 Oct; 367(14):1364; author reply 1365. PubMed ID: 23034028
[No Abstract] [Full Text] [Related]
18. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
Andrews MC; Behren A; Chionh F; Mariadason J; Vella LJ; Do H; Dobrovic A; Tebbutt N; Cebon J
J Clin Oncol; 2013 Dec; 31(35):e448-51. PubMed ID: 24190114
[No Abstract] [Full Text] [Related]
19. Complicated ventricular arrhythmia and hematologic myeloproliferative disorder in RIT1-associated Noonan syndrome: Expanding the phenotype and review of the literature.
Aly SA; Boyer KM; Muller BA; Marini D; Jones CH; Nguyen HH
Mol Genet Genomic Med; 2020 Jul; 8(7):e1253. PubMed ID: 32396283
[TBL] [Abstract][Full Text] [Related]
20. Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.
Cavé H; Caye A; Ghedira N; Capri Y; Pouvreau N; Fillot N; Trimouille A; Vignal C; Fenneteau O; Alembik Y; Alessandri JL; Blanchet P; Boute O; Bouvagnet P; David A; Dieux Coeslier A; Doray B; Dulac O; Drouin-Garraud V; Gérard M; Héron D; Isidor B; Lacombe D; Lyonnet S; Perrin L; Rio M; Roume J; Sauvion S; Toutain A; Vincent-Delorme C; Willems M; Baumann C; Verloes A
Eur J Hum Genet; 2016 Aug; 24(8):1124-31. PubMed ID: 26757980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
